Genmab: New deal shows our commercial aim
Following the reinforcement of the company’s financial foundation, Genmab’s CEO will now implement a much more commercial mindset in all aspects of drug development and the company will possibly begin to market drugs on its own.
BY STEFAN SINGH KAILAY
Genmab’s chief executive, Jan van de Winkel, is thrilled with the partnership the company struck with US-based Seattle Genetics last week, not least because of what the deal exemplifies – but more about that later.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
